This Executive Overview outlines the proof-of-concept study completed by Predictive Oncology to illustrate the power of our active machine learning (AI) platform paired with our biobank of over 150,000 primary patient dissociated tumor samples. The described validation results demonstrate the generation of a predictive model that was able to accurately predict drug response across 130 samples and 175 drugs.

Predictive Oncology
Accepting new applications for ACE program 2025
Following the generation of successful results with the University of Michigan through the ACE program, Predictive Oncology is now actively calling for submissions for a